Optimizing the Treatment of CLL With Novel Therapies
Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.
Read More
Noncovalent BTK Inhibitors in CLL
Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.
Read More
Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab
The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.
Read More
Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors
Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.
Read More
BTK Inhibitors as Frontline Therapy for CLL
The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.
Read More
Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL
November 12th 2021Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Read More